Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1963 1
1964 1
1969 1
1971 3
1974 1
1975 1
1979 1
1980 2
1994 2
1996 1
2003 1
2006 1
2007 1
2008 1
2009 1
2012 2
2013 1
2014 2
2017 1
2018 3
2019 2
2020 4
2021 4
2022 12
2023 5
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2.
Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, Pade C, Gibbons JM, Le Bert N, Tan AT, Jeffery-Smith A, Tan CCS, Tham CYL, Kucykowicz S, Aidoo-Micah G, Rosenheim J, Davies J, Johnson M, Jensen MP, Joy G, McCoy LE, Valdes AM, Chain BM, Goldblatt D, Altmann DM, Boyton RJ, Manisty C, Treibel TA, Moon JC; COVIDsortium Investigators; van Dorp L, Balloux F, McKnight Á, Noursadeghi M, Bertoletti A, Maini MK. Swadling L, et al. Among authors: gibbons jm. Nature. 2022 Jan;601(7891):110-117. doi: 10.1038/s41586-021-04186-8. Epub 2021 Nov 10. Nature. 2022. PMID: 34758478 Free PMC article.
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure.
Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin KM, Muñoz Sandoval D, Pieper FP, Butler DK, Liu S, Joy G, Forooghi N, Treibel TA, Manisty C, Moon JC; COVIDsortium Investigators§; COVIDsortium Immune Correlates Network§; Semper A, Brooks T, McKnight Á, Altmann DM, Boyton RJ, Abbass H, Abiodun A, Alfarih M, Alldis Z, Altmann DM, Amin OE, Andiapen M, Artico J, Augusto JB, Baca GL, Bailey SNL, Bhuva AN, Boulter A, Bowles R, Boyton RJ, Bracken OV, O'Brien B, Brooks T, Bullock N, Butler DK, Captur G, Carr O, Champion N, Chan C, Chandran A, Coleman T, Couto de Sousa J, Couto-Parada X, Cross E, Cutino-Moguel T, D'Arcangelo S, Davies RH, Douglas B, Di Genova C, Dieobi-Anene K, Diniz MO, Ellis A, Feehan K, Finlay M, Fontana M, Forooghi N, Francis S, Gibbons JM, Gillespie D, Gilroy D, Hamblin M, Harker G, Hemingway G, Hewson J, Heywood W, Hickling LM, Hicks B, Hingorani AD, Howes L, Itua I, Jardim V, Lee WJ, Jensen M, Jones J, Jones M, Joy G, Kapil V, Kelly C, Kurdi H, Lambourne J, Lin KM, Liu S, Lloyd A, Louth S, Maini MK, Mandadapu V, Manisty C, McKnight Á, Menacho K, Mfuko C, Mills K, Millward S, Mitchelmore O, Moon C, Moon J, Muñoz Sandoval D, Murray SM, Noursadeghi M, Otter… See abstract for full author list ➔ Reynolds CJ, et al. Among authors: gibbons jm. Science. 2022 Jul 15;377(6603):eabq1841. doi: 10.1126/science.abq1841. Epub 2022 Jul 15. Science. 2022. PMID: 35699621 Free PMC article.
Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity.
Altmann DM, Reynolds CJ, Joy G, Otter AD, Gibbons JM, Pade C, Swadling L, Maini MK, Brooks T, Semper A, McKnight Á, Noursadeghi M, Manisty C, Treibel TA, Moon JC; COVIDsortium investigators; Boyton RJ. Altmann DM, et al. Among authors: gibbons jm. Nat Commun. 2023 Aug 23;14(1):5139. doi: 10.1038/s41467-023-40460-1. Nat Commun. 2023. PMID: 37612310 Free PMC article.
Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection.
Milighetti M, Peng Y, Tan C, Mark M, Nageswaran G, Byrne S, Ronel T, Peacock T, Mayer A, Chandran A, Rosenheim J, Whelan M, Yao X, Liu G, Felce SL, Dong T, Mentzer AJ, Knight JC, Balloux F, Greenstein E, Reich-Zeliger S, Pade C, Gibbons JM, Semper A, Brooks T, Otter A, Altmann DM, Boyton RJ, Maini MK, McKnight A, Manisty C, Treibel TA, Moon JC; COVIDsortium Investigators; Noursadeghi M, Chain B. Milighetti M, et al. Among authors: gibbons jm. iScience. 2023 Jun 16;26(6):106937. doi: 10.1016/j.isci.2023.106937. Epub 2023 May 22. iScience. 2023. PMID: 37275518 Free PMC article.
Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection.
Captur G, Moon JC, Topriceanu CC, Joy G, Swadling L, Hallqvist J, Doykov I, Patel N, Spiewak J, Baldwin T, Hamblin M, Menacho K, Fontana M, Treibel TA, Manisty C, O'Brien B, Gibbons JM, Pade C, Brooks T, Altmann DM, Boyton RJ, McKnight Á, Maini MK, Noursadeghi M, Mills K, Heywood WE; UK COVIDsortium Investigators. Captur G, et al. Among authors: gibbons jm. EBioMedicine. 2022 Nov;85:104293. doi: 10.1016/j.ebiom.2022.104293. Epub 2022 Sep 28. EBioMedicine. 2022. PMID: 36182629 Free PMC article.
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants.
Reynolds CJ, Gibbons JM, Pade C, Lin KM, Sandoval DM, Pieper F, Butler DK, Liu S, Otter AD, Joy G, Menacho K, Fontana M, Smit A, Kele B, Cutino-Moguel T, Maini MK, Noursadeghi M; COVIDsortium Immune Correlates Network‡; Brooks T, Semper A, Manisty C, Treibel TA, Moon JC; COVIDsortium Investigators‡; McKnight Á, Altmann DM, Boyton RJ. Reynolds CJ, et al. Among authors: gibbons jm. Science. 2022 Jan 14;375(6577):183-192. doi: 10.1126/science.abm0811. Epub 2021 Dec 2. Science. 2022. PMID: 34855510 Free PMC article.
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.
Abhishek A, Peckham N, Pade C, Gibbons JM, Cureton L, Francis A, Barber V, Williams JAE, Appelbe D, Eldridge L, Julier P, Altmann DM, Bluett J, Brooks T, Coates LC, Rombach I, Semper A, Otter A, Valdes AM, Nguyen-Van-Tam JS, Williams HC, Boyton RJ, McKnight Á, Cook JA; VROOM study investigators. Abhishek A, et al. Among authors: gibbons jm. Lancet Rheumatol. 2024 Feb;6(2):e92-e104. doi: 10.1016/S2665-9913(23)00298-9. Epub 2023 Dec 12. Lancet Rheumatol. 2024. PMID: 38267107 Free article. Clinical Trial.
HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19.
Astbury S, Reynolds CJ, Butler DK, Muñoz-Sandoval DC, Lin KM, Pieper FP, Otter A, Kouraki A, Cusin L, Nightingale J, Vijay A, Craxford S, Aithal GP, Tighe PJ, Gibbons JM, Pade C, Joy G, Maini M, Chain B, Semper A, Brooks T, Ollivere BJ, McKnight Á, Noursadeghi M, Treibel TA, Manisty C, Moon JC; COVIDsortium Investigators*; Valdes AM, Boyton RJ, Altmann DM. Astbury S, et al. Among authors: gibbons jm. Immunology. 2022 May;166(1):68-77. doi: 10.1111/imm.13450. Epub 2022 Mar 8. Immunology. 2022. PMID: 35156709 Free PMC article.
Curbside particulate matter and susceptibility to SARS-CoV-2 infection.
Miyashita L, Foley G, Semple S, Gibbons JM, Pade C, McKnight Á, Grigg J. Miyashita L, et al. Among authors: gibbons jm. J Allergy Clin Immunol Glob. 2023 Jul 8;2(4):100141. doi: 10.1016/j.jacig.2023.100141. eCollection 2023 Nov. J Allergy Clin Immunol Glob. 2023. PMID: 37781647 Free PMC article.
Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response.
Doykov I, Baldwin T, Spiewak J, Gilmour KC, Gibbons JM, Pade C, Reynolds CJ, Áine McKnight, Noursadeghi M, Maini MK, Manisty C, Treibel T, Captur G, Fontana M, Boyton RJ, Altmann DM, Brooks T, Semper A; UK COVIDsortium Investigators; Moon JC, Kevin Mills, Heywood WE. Doykov I, et al. Among authors: gibbons jm. Cell Rep Methods. 2022 Sep 19;2(9):100279. doi: 10.1016/j.crmeth.2022.100279. Epub 2022 Aug 12. Cell Rep Methods. 2022. PMID: 35975199 Free PMC article.
53 results